Pembrolizumab combined with weekly paclitaxel ± bevacizumab reduced death risk by 18% and improved median OS by 3.7 months versus paclitaxel ± bevacizumab in all comers. Progression-free survival ...
Hosted on MSN
Survival rates for cancer are the highest they’ve ever been — but these 3 will cause the most deaths in 2026
Cancer statistics have reached new heights — in good and not-so-good ways. The American Cancer Society (ACS) released its annual report on cancer trends this week, showing for the first time that more ...
An objective response rate of 50.5% was observed with raludotatug deruxtecan across all dose levels in these patients in the phase 2 part of REJOICE-Ovarian01 Phase 3 part of REJOICE-Ovarian01 to ...
People are living longer after a cancer diagnosis than ever before. According to a new report from the American Cancer Society (ACS), 70% of those who receive a cancer diagnosis survive for five or ...
People who have received a cancer diagnosis are living longer than ever, according to a new report from the American Cancer Society (ACS). Decades of cancer research have led to more effective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results